Literature DB >> 2873222

Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity.

R W Gristwood, R J Eden, D A Owen, E M Taylor.   

Abstract

The pharmacological properties of SK&F 94120 on the cardiovascular system have been studied in laboratory animal species. The compound was shown to have positive inotropic activity on hearts from guinea-pig, cat, dog and marmoset in-vitro and in cat and dog in-vivo. These responses in-vivo occurred in association with minimal changes in heart rate. Positive inotropic activity was not caused by SK&F 94120 in rat or hamster hearts in-vitro, thereby indicating a species dependence in myocardial response. SK&F 94120 was shown to have vasodilator activity in cats in-vivo. Detailed studies carried out on anaesthetized cats indicated that the compound caused a balanced dilatation of both resistance and capacitance blood vessels. Haemodynamic studies in anaesthetized cats indicated that, as a consequence of the positive inotropic and vasodilator actions, SK&F 94120 causes significant increases in cardiac output and stroke volume. Studies in conscious dogs showed the compound to be active as a positive inotrope after oral administration. The above properties suggest that this compound possesses useful haemodynamic properties for the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873222     DOI: 10.1111/j.2042-7158.1986.tb04609.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  N Komas; C Lugnier; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

2.  In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action.

Authors:  R W Gristwood; M B Comer; R J Eden; E M Taylor; J A Turner; M Wallduck; D A Owen
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

Review 3.  Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

Authors:  I P Hall
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

4.  The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site.

Authors:  C D Nicholson; S A Jackman; R Wilke
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

5.  Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.

Authors:  M Shahid; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

6.  Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices.

Authors:  R A Challiss; C D Nicholson
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

7.  Control of cyclic AMP levels in primary cultures of human tracheal smooth muscle cells.

Authors:  I P Hall; S Widdop; P Townsend; K Daykin
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

8.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

9.  Studies on the cardiac actions of flosequinan in vitro.

Authors:  R W Gristwood; J Beleta; J Bou; I Cardelús; A G Fernández; J Llenas; P Berga
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

Authors:  J Cortijo; J Bou; J Beleta; I Cardelús; J Llenas; E Morcillo; R W Gristwood
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.